ロード中...

Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations

Imatinib is an inhibitor of the Abl tyrosine kinase domain that is effective in the treatment of chronic myelogenic leukemia (CML). Although imatinib binds tightly to the Abl kinase domain, its affinity for the closely related kinase domain of c-Src is at least 2000-fold lower. Imatinib recognition...

詳細記述

保存先:
書誌詳細
主要な著者: Seeliger, Markus A., Ranjitkar, Pratistha, Kasap, Corynn, Shan, Yibing, Shaw, David E., Shah, Neil P., Kuriyan, John, Maly, Dustin J.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678021/
https://ncbi.nlm.nih.gov/pubmed/19276351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-3953
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!